WallStSmart
XBIT

XBiotech Inc

NASDAQ: XBIT · HEALTHCARE · BIOTECHNOLOGY

$2.47
+0.00% today

Updated 2026-06-05

Market cap
$71.34M
P/E ratio
P/S ratio
12.23x
EPS (TTM)
$-1.31
Dividend yield
52W range
$2 – $4
Volume
0.0M

XBiotech Inc (XBIT) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-25.90%
ROA
-18.80%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2012$-15.16M
2013$-9.93M
2014$0.00$-21.72M
2015$0.00$-37.48M
2016$0.00$-52.76M
2017$0.00$-33.15M
2018$0.00$-21.14M
2019$12.68M$668.63M-18.62%-246.30%5,272.68%
2020$44.00M$-11.22M21.48%-41.54%-25.50%
2021$18.39M$-17.41M68.36%-136.36%-94.67%
2022$4.01M$-32.90M83.77%-860.10%-820.45%
2023$300000.00$-24.56M-581.33%-12,503.33%-8,185.67%
2024$0.00$-38.53M
2025$0.00$-45.54M

Frequently asked questions

What is XBiotech Inc's revenue?

XBiotech Inc's trailing twelve-month revenue is $300000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does XBIT generate?

XBIT produced $-40.21M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is XBIT's balance sheet healthy?

XBIT holds $125.55M in cash and equivalents against — in long-term debt, on $140.35M of shareholder equity. That debt is best read against the cash flow the business throws off each year.